Shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $13.50.
Several brokerages have commented on CDMO. StockNews.com upgraded shares of Avid Bioservices to a “sell” rating in a research report on Tuesday, September 10th. Royal Bank of Canada boosted their price target on Avid Bioservices from $8.00 to $12.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Stephens reaffirmed an “overweight” rating and issued a $12.00 price objective on shares of Avid Bioservices in a research note on Tuesday, September 10th. Finally, William Blair reissued a “market perform” rating on shares of Avid Bioservices in a research note on Tuesday, September 10th.
Get Our Latest Stock Report on CDMO
Insider Activity
Institutional Investors Weigh In On Avid Bioservices
Several hedge funds have recently added to or reduced their stakes in CDMO. Millennium Management LLC increased its position in Avid Bioservices by 15.8% in the 2nd quarter. Millennium Management LLC now owns 5,099,529 shares of the biopharmaceutical company’s stock valued at $36,411,000 after acquiring an additional 695,512 shares during the period. Vanguard Group Inc. grew its stake in shares of Avid Bioservices by 1.3% in the first quarter. Vanguard Group Inc. now owns 3,665,188 shares of the biopharmaceutical company’s stock worth $24,557,000 after purchasing an additional 47,315 shares during the last quarter. AltraVue Capital LLC increased its holdings in Avid Bioservices by 7.6% in the second quarter. AltraVue Capital LLC now owns 3,395,263 shares of the biopharmaceutical company’s stock valued at $24,242,000 after purchasing an additional 239,343 shares during the period. 12 West Capital Management LP bought a new position in Avid Bioservices during the 1st quarter worth $18,425,000. Finally, Point72 Asset Management L.P. lifted its holdings in Avid Bioservices by 51.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,673,050 shares of the biopharmaceutical company’s stock worth $19,086,000 after buying an additional 904,733 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.
Avid Bioservices Stock Up 0.7 %
Shares of NASDAQ CDMO opened at $10.63 on Friday. The stock has a market capitalization of $678.09 million, a P/E ratio of -4.81 and a beta of 1.38. The stock’s fifty day moving average is $10.66 and its 200 day moving average is $8.77. Avid Bioservices has a 52 week low of $4.07 and a 52 week high of $12.48. The company has a debt-to-equity ratio of 2.74, a quick ratio of 1.05 and a current ratio of 1.46.
Avid Bioservices (NASDAQ:CDMO – Get Free Report) last released its earnings results on Monday, September 9th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $40.17 million for the quarter, compared to analyst estimates of $39.50 million. Avid Bioservices had a negative net margin of 101.26% and a negative return on equity of 16.53%. Sell-side analysts forecast that Avid Bioservices will post -0.34 earnings per share for the current fiscal year.
Avid Bioservices Company Profile
Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.
Featured Articles
- Five stocks we like better than Avid Bioservices
- How to buy stock: A step-by-step guide for beginners
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Are Dividend Champions? How to Invest in the Champions
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.